

Monthly statement of total voting rights and shares forming the company's share capital

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com

Date	Number of shares outstanding	Total voting rights, gross ⁽¹⁾	Total voting rights, net ⁽²⁾
May 31, 2016	14 658 118	14 658 118	14 596 551

⁽¹⁾ The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2017.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA; a new frontier pioneered by GeNeuro since 2006 based on 15 years of R&D at Institut Mérieux and INSERM.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Contacts

GeNeuro

Jesús Martin-Garcia
Chairman and CEO
investors@geneuro.com
+41 22 794 50 85

NewCap (France)

Julien Perez (Investors)
01 44 71 98 52
Nicolas Merigeau (media)
01 44 71 94 98
geneuro@newcap.eu